retatrutide type 2 diabetes phase 2 trial results as a Novel Treatment for Obesity and Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

For its second application, the FDA set a PDUFA date of May 14, 2024, but this was pushed back by three months after Ascendis filed a major amendment to the application

Luo C, Jian C, Liao Y, Huang Q, Wu Y, Liu X, et al

Researchers have explored 5-Amino-1MQ in studies focused on metabolic signalling dynamics, enzyme-associated pathways, and broader biochemical processes relating to cellular function and regulation

In cancer cells, genetic and epigenetic dysregulation of MYC expression and the loss of checkpoint components unleash the ability of MYC to promote cell growth, eventually leading to malignant transformation 176